Martin Reck

Martin Reck is a thoracic oncologist who co-led the KEYNOTE-024 trial and has been instrumental in validating PD-L1 expression as a predictive biomarker for pembrolizumab monotherapy in NSCLC. He has contributed to long-term follow-up analyses of KEYNOTE-024 and other first-line IO trials, providing evidence on durability of responses. His work on biomarker refinement for immunotherapy selection in NSCLC has shaped European treatment guidelines. Reck is a frequent presenter at ESMO, ASCO, and WCLC on first-line NSCLC management.